Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | FABP6 | P51161 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30545957 | 1.00 | GRM5 (0.68) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL30524061 | 0.84 | PARP1 (0.68) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL9475799 | 0.84 | PARP1 (0.68) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL26523922 | 0.84 | GRM5 (0.51) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL10243599 | 0.81 | PARP10 (0.74) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL794160 | 0.81 | PARP10 (0.74) | GRM5PARP10PARP1PARP11FABP6 | |
| SCHEMBL34461053 | 0.79 | GRM5 (0.50) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL1888691 | 0.78 | PARP10 (0.60) | GRM5GSK3BPARP10PARP1PARP11 | |
| SCHEMBL505100 | 0.78 | GRM5 (1.00) | GRM5CLK4NTRK1FLT3GSK3B | |
| SCHEMBL8163189 | 0.77 | GSK3B (0.75) | GRM5CLK4NTRK1FLT3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118231660-A | Positive electrode slurry, positive electrode plate and sodium ion battery | 比亚迪股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-102911109-A | Preparation method of 6-amino-5-fluorine-1-isoindolinone | UNIV SHANXI MEDICAL | 2013-02-06 | — | — | CN | claimed |
| EP-4734979-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025006723-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| CN-118231660-A | Positive electrode slurry, positive electrode plate and sodium ion battery | 比亚迪股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2611790-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611798-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| CN-102911109-A | Preparation method of 6-amino-5-fluorine-1-isoindolinone | UNIV SHANXI MEDICAL | 2013-02-06 | — | — | CN | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030990-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-5254578-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1993-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, TYK2, LCK | GRM5 2470/4885CLK4 266/4885NTRK1 589/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | GRM5 3992/4885CLK4 1483/4885NTRK1 3912/4885 |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | GRM5 33/4885CLK4 4767/4885NTRK1 385/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | GRM5 3992/4885CLK4 1483/4885NTRK1 3912/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | GRM5 3992/4885CLK4 1483/4885NTRK1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.